ATE76579T1 - Interferon-zusammensetzungen. - Google Patents

Interferon-zusammensetzungen.

Info

Publication number
ATE76579T1
ATE76579T1 AT86309134T AT86309134T ATE76579T1 AT E76579 T1 ATE76579 T1 AT E76579T1 AT 86309134 T AT86309134 T AT 86309134T AT 86309134 T AT86309134 T AT 86309134T AT E76579 T1 ATE76579 T1 AT E76579T1
Authority
AT
Austria
Prior art keywords
interferon
interferon compositions
compositions
viruses
delta
Prior art date
Application number
AT86309134T
Other languages
English (en)
Inventor
Paul Jason Leibowitz
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE76579T1 publication Critical patent/ATE76579T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT86309134T 1985-12-11 1986-11-21 Interferon-zusammensetzungen. ATE76579T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/807,887 US4806347A (en) 1985-12-11 1985-12-11 Interferon combinations
EP86309134A EP0225759B1 (de) 1985-12-11 1986-11-21 Interferon-Zusammensetzungen

Publications (1)

Publication Number Publication Date
ATE76579T1 true ATE76579T1 (de) 1992-06-15

Family

ID=25197366

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86309134T ATE76579T1 (de) 1985-12-11 1986-11-21 Interferon-zusammensetzungen.

Country Status (7)

Country Link
US (1) US4806347A (de)
EP (1) EP0225759B1 (de)
JP (1) JPS62145029A (de)
AT (1) ATE76579T1 (de)
DE (1) DE3685484D1 (de)
ES (1) ES2036526T3 (de)
GR (1) GR3005362T3 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE74517T1 (de) * 1987-01-20 1992-04-15 Schering Corp Behandlung von einigen leukaemien mit einer zusammensetzung von interferon-gamma und interferon-alpha.
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
AU782402B2 (en) 1999-09-17 2005-07-28 Wellstat Biologics Corporation Oncolytic virus
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
CN1564693A (zh) * 2001-10-05 2005-01-12 印特缪恩股份有限公司 治疗肝纤维化和丙型肝炎病毒感染的方法
AU2003225670A1 (en) * 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2004078206A1 (en) * 2003-03-07 2004-09-16 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
DK2388315T3 (da) 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
EP2305696A3 (de) 2005-07-25 2011-10-12 Intermune, Inc. Makrocyclische Inhibitoren der Replikation des Hepatitis-C-Virus
EA200801050A1 (ru) 2005-10-11 2008-12-30 Интермьюн, Инк. Соединения и способы ингибирования репликации вирусного гепатита с

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
ES8302778A1 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
EP0107498B1 (de) * 1982-10-25 1990-05-16 Genentech, Inc. Synergistische Humaninterferonaktivität
EP0146903A3 (de) * 1983-12-19 1987-07-22 Schering Corporation Herstellung eines ein Hybrid-Interferon-Spezies kodierenden Vektors

Also Published As

Publication number Publication date
JPS62145029A (ja) 1987-06-29
ES2036526T3 (es) 1993-06-01
DE3685484D1 (de) 1992-07-02
US4806347A (en) 1989-02-21
EP0225759A3 (en) 1989-02-08
EP0225759B1 (de) 1992-05-27
EP0225759A2 (de) 1987-06-16
GR3005362T3 (de) 1993-05-24

Similar Documents

Publication Publication Date Title
EP0154344A3 (en) Antiviral pharmaceutical preparations and methods for their use
HUT37891A (en) Process for preparing synegretic mixtures of interferones and tumor necrosis factor
IT8522574A0 (it) Composizione farmaceutica eprocedimento per trattare il corpo umano con essa.
FI943750A0 (fi) Menetelmä nekroositekijän valmistamiseksi
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
DE3851002D1 (de) Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung.
DE3685484D1 (de)
FI940375A0 (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
UA42806C2 (uk) Система для одночасного трансдермального введення кількох активних начал
ATE81004T1 (de) Laktamimide in der behandlung arzneiresistenter protozoeninjektionen.
NO890046D0 (no) Disubstituerte pyridiner.
DE69830241D1 (de) Verwendung von n-substituierten 1,5-dideoxy-1,5-imino-d-glucitol verbindungen in der kombinationstherapie der vom hepatitisvirus verursachten infektionen
DE3851456D1 (de) Synergetische immunostimulierende Zusammensetzung und ihre Verwendung.
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
ES2019634B3 (es) Terapia con clorfeniramina.
DE3767175D1 (de) Therapeutische zusammenstellungen auf basis von 3-alkoxyflavonen und derivate von 3-alkoxyflavonen.
IT1237088B (it) N,n'-di-(trimetossibenzoil) piperazine 2-carbonil sostituite, procedimento per preparare le stesse e composti terapeutici che le contengono.
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
DE3674997D1 (de) Holzbehandlungszusammensetzung.
IT1237087B (it) N,n'-di-(trimetossibenzoil) piperazine 2-metossicarbonil sostituite, procedimento per preparare le stesse e composti terapeutici che le contengono.
ATE87314T1 (de) Platin-arzneimittel.
DK222988D0 (da) Farmaceutiske praeparater indeholdende ornithin-decarboxylase-inhibitorer
ES285527U (es) Estante perfeccionado
MY110041A (en) Composition and method of treating hepatitis c
RO84177B1 (ro) Metoda de rahianestezie